BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Med-tech gainers and losers for Jan. 11-15, 2021

Jan. 15, 2021
No Comments
The top 10 med-tech stock gainers and losers for the week.
Read More
2020 pandemic illustration

Volume up, value down, but digital tops 2020’s deal-making efforts

Jan. 14, 2021
By Karen Carey
No Comments
The volume of med-tech deals and M&As in 2020 reached impressive levels, well above 2019, primarily due to the demands of a global pandemic, although the disclosed values of those alliances fell dramatically short. Even so, the spotlight that shined on digital health and diagnostics throughout the challenging year has potentially set up the med-tech industry for an influx of attention going forward.
Read More
2020 formed with $100 stacks

Massive amounts of capital raised amid a raging pandemic

Jan. 12, 2021
By Peter Winter
No Comments
A decade from now, 2020 likely will be considered a year like no other in terms of the massive amounts of capital raised amid a raging pandemic. Financing transactions of all types smashed records and in terms of volume hit 1,580, a total that was 42% higher than last year.
Read More
Handshake with cityscape and businesspeople

Robust deals hit $197B in 2020; M&As ready to rebound

Jan. 12, 2021
By Karen Carey
No Comments
With several deals and M&As falling within the highest values on record, 2020 turned out to be a solid year for the biopharma industry. Expectations are optimistic moving into 2021, when the U.S. will welcome a new president and its citizens should reach herd immunity from COVID-19.
Read More
Gold coins and sprouting plants

Already a strong January for VCs, as 2020 signs off with $134B-plus

Jan. 11, 2021
By Karen Carey
No Comments
The attention the COVID-19 pandemic drew to the biopharma industry, the ease and convenience of virtual meetings, as well as massive amounts of available capital, all led to an extraordinary year for financings in 2020. The momentum appears to be continuing, particularly with venture capital rounds.
Read More
2020 formed with $100 stacks

Massive amounts of capital raised amid a raging pandemic

Jan. 11, 2021
By Peter Winter
No Comments
A decade from now, 2020 likely will be considered a year like no other in terms of the massive amounts of capital raised amid a raging pandemic. Financing transactions of all types smashed records and in terms of volume hit 1,580, a total that was 42% higher than last year despite the serious disruptions to normal business operations.
Read More
ICYMI illustration

ICYMI: Week in review, Jan. 4-8, 2021

Jan. 11, 2021
No Comments
A quick look back at top stories.
Read More

Money raised by biopharma: 2021 vs. 2020 vs. 2019

Jan. 8, 2021
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-7, 2021

Jan. 8, 2021
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Hand holding IPO, financial icons

Biopharma money raised by quarter in 2020 (US$M)

Jan. 8, 2021
No Comments
Biopharma money raised to-date and by quarter in 2020, including public, private and other financings.
Read More
Previous 1 2 … 99 100 101 102 103 104 105 106 107 … 173 174 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 21, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 21, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing